The omega-3 fatty acids EPA and DHA decrease plasma F(2)-isoprostanes: Results from two placebo-controlled interventions
Mas E, Woodman RJ, Burke V, Puddey IB, Beilin LJ, Durand T, Mori TA
Free radical research · 75 citas
Etiquetas de revisión
Solo mecanismosDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Solo mecanismos
Quién lo pagó
- Financiación
- Financiación independiente
- Universidad u hospital
- Hospital Research Foundation
- Universidad u hospital
- Royal Perth Hospital Medical Research Foundation
- Gobierno
- National Institutes of Health
- Gobierno
- National Health and Medical Research Council
- Gobierno
- National Medical Research Council
Según 5 financiadores declarados.
Publicación
- Publicado
- 2010-06-14 · Free Radic Res · vol. 44 · número 9 · págs. 983–990
- Editorial
- Taylor & Francis
- Citado
- 94 citas · más que el 98% de estudios similares · 9.0× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 55 trabajos
- Acceso
- De pago
- Áreas de investigación
- Fatty Acid Research and Health · Antioxidant Activity and Oxidative Stress · Edible Oils Quality and Analysis
- Palabras clave
- omega-3 fatty acids, eicosapentaenoic acid, docosahexaenoic acid, F2-isoprostanes, lipid peroxidation, oxidative stress, plasma biomarkers, dyslipidemia, hypertension, type 2 diabetes, arachidonic acid, olive oil placebo
- MeSH
- humans, diabetes mellitus, type 2, fatty acids, omega-3, docosahexaenoic acids, eicosapentaenoic acid, f2-isoprostanes, placebos, postmenopause, dietary supplements, adult, aged, middle aged, female, male, hyperlipidemias, young adult
7 autores
- Emilie Mas🇦🇺 · autor de correspondenciaThe University of Western Australia; Royal Perth Hospital
- Richard John Woodman🇦🇺The University of Western Australia; Royal Perth Hospital
- Valerie Burke🇦🇺The University of Western Australia; Royal Perth Hospital
- Ian B. Puddey🇦🇺The University of Western Australia; Royal Perth Hospital
- Lawrence Joseph Beilin🇦🇺The University of Western Australia; Royal Perth Hospital
- Thierry Durand🇫🇷Centre National de la Recherche Scientifique; Institut des Biomolécules Max Mousseron
- Trevor Anthony Mori🇦🇺The University of Western Australia; Royal Perth Hospital
Resumen
El texto original del estudio, en el idioma en que se publicó.
Omega-3 (omega3) fatty acids, particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), protect against cardiovascular disease. Despite these benefits, concern remains that omega3 fatty acids may increase lipid peroxidation. It has previously been shown that urinary F(2)-isoprostanes (F(2)-IsoPs) were reduced following omega3 fatty acid supplementation in humans. It is now determined whether EPA or DHA supplementation affects plasma F(2)-IsoPs. In two 6-week placebo-controlled interventions, Study A: overweight, dyslipidaemic men; and Study B: treated-hypertensive Type 2 diabetic, patients were randomized to 4 g daily EPA, DHA. Post-intervention plasma F(2)-IsoPs were significantly reduced by EPA (24% in Study A, 19% in Study B) and by DHA (14% in Study A, 23% in Study B) relative to the olive oil group. The fall in plasma F(2)-IsoPs was not altered in analyses that corrected for changes in plasma arachidonic acid, which was reduced with EPA and DHA supplementation. Neither F(3)- nor F(4)-IsoPs were observed in plasma in both studies. These results show that in humans, EPA and DHA reduce in vivo oxidant stress as measured in human plasma and urine.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.